Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia



Rating:

Share or cite this content

Citations should be made in the following way:
L. Richeldi (Rome, Italy), K. Anstrom (North Carolina, United States of America), J. Behr (Munich, Germany), T. Corte (New South Wales, Australia), V. Cottin (Lyon, France), G. Jenkins (Nottingham, United Kingdom), N. Kamath (Welwyn Garden City, United Kingdom), Y. Inoue (Osaka, Japan), L. Islam (Welwyn Garden City, United Kingdom), S. Nathan (Virginia, United States of America), G. Raghu (Washington, United States of America), J. Randhawa (Welwyn Garden City, United Kingdom), S. Walsh (London, United Kingdom), F. Martinez (New York, United States of America). Recombinant human pentraxin-2 for idiopathic pulmonary fibrosis: Design of STARSCAPE-OLE, a Phase III open label extension study. 461

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Phase 2, multi-center, open label, single-arm study of TAS-115, a novel multi-kinase inhibitor in patients with idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772) Source: Eur Respir J, 52 (6) 1801130; 10.1183/13993003.01130-2018 Year: 2018 Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Challenges in setting up Phase III idiopathic pulmonary fibrosis studies during the COVID-19 pandemic: Experience from the STARSCAPE program Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Exploratory analysis of phase III trial of pirfenidone: Most effective population in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Idiopathic pulmonary fibrosis (IPF): observations from a Phase 2 trial of GLPG1205 (PINTA) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON) Source: International Congress 2015 – Treatment of IPF Year: 2015 Fatigue in patients with idiopathic pulmonary fibrosis (IPF) from the pooled pirfenidone (PFD) Phase III trials Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward Source: Eur Respir J 2013; 42: 1446-1448 Year: 2013 Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (3) 1800663; 10.1183/13993003.00663-2018 Year: 2019 Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment I Year: 2016 Transplantation of alveolar type II cells in pulmonary fibrosis: experimental studies, MSC in IPF trials Source: International Congress 2014 – Targeting lung fibrosis: from bench to bedside Year: 2014 Extended analysis of phase III trial of pirfenidone: More pronounced effect in mild impairment of patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials Source: Eur Respir J 2016; 47: 243-253 Year: 2016 Late Breaking Abstract - Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease - COPD-ST2OP: a phase IIa, placebo-controlled trial Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 Preliminary results of a prospective, multicentric randomized study comparing Interferon Gamma-1b (IFN-γ) and colchicine in the treatment of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2003 - Interstitial lung diseases Year: 2003 Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study Source: Eur Respir J, 59 (2) 2100746; 10.1183/13993003.00746-2021 Year: 2022 Survival in idiopathic pulmonary fibrosis: results of the IFIGENIA follow up study Source: Eur Respir J 2004; 24: Suppl. 48, 254s Year: 2004 Results of a phase 2 study of GLPG1205 for idiopathic pulmonary fibrosis (PINTA) Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021 Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study Source: International Congress 2018 – Notable Studies in Asthma Year: 2018